Peer-reviewed review (JOMES 35(1):38) of amylin physiology and amylin-based therapeutics, positioning pramlintide as the only FDA-approved amylin analog (approved 2005) for T1DM and T2DM, with modest HbA1c and weight benefits and multiple-daily-injection limits on adoption. It surveys the amylin-agonist revival — cagrilintide, CagriSema, and next-generation co-agonists — that followed Symlin's commercial decline.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.